<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2448-8909</journal-id>
<journal-title><![CDATA[Medicina crítica (Colegio Mexicano de Medicina Crítica)]]></journal-title>
<abbrev-journal-title><![CDATA[Med. crít. (Col. Mex. Med. Crít.)]]></abbrev-journal-title>
<issn>2448-8909</issn>
<publisher>
<publisher-name><![CDATA[Colegio Mexicano de Medicina Crítica A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2448-89092018000500258</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Puntaje LVIS como predictor de mortalidad en choque séptico]]></article-title>
<article-title xml:lang="en"><![CDATA[LVIS as mortality predictor in septic shock]]></article-title>
<article-title xml:lang="pt"><![CDATA[Pontuação LVIS como preditor de mortalidade em choque séptico]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Castillejos Suastegui]]></surname>
<given-names><![CDATA[Humberto Alfonso]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Monares Zepeda]]></surname>
<given-names><![CDATA[Enrique]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pedraza Montenegro]]></surname>
<given-names><![CDATA[Axel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Contreras Contreras]]></surname>
<given-names><![CDATA[Alma Rosa]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gómez Moctezuma]]></surname>
<given-names><![CDATA[Careli]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Aguirre Sánchez]]></surname>
<given-names><![CDATA[Janet Silvia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Camarena Alejo]]></surname>
<given-names><![CDATA[Gilberto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Franco Granillo]]></surname>
<given-names><![CDATA[Juvenal]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Centro Médico ABC  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>10</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>10</month>
<year>2018</year>
</pub-date>
<volume>32</volume>
<numero>5</numero>
<fpage>258</fpage>
<lpage>264</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2448-89092018000500258&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2448-89092018000500258&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2448-89092018000500258&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Introducción:  El uso de vasopresores en choque séptico es parte fundamental del tratamiento. El uso de un puntaje que integre los múltiples vasopresores e inotrópicos como LVIS (levosimendan vasopressor inotropic score), puede ser de utilidad para el seguimiento y pronóstico de estos pacientes. Se ha estudiado en población pediátrica y no ha sido validada en población adulta.  Material y métodos:  Estudio retrospectivo, longitudinal, retrolectivo en pacientes adultos admitidos a UCI con diagnóstico de choque séptico con el fin de investigar si el puntaje LVIS es capaz de predecir mortalidad y lesión renal aguda. Seguimiento a 30 días.  Resultados:  Incluimos 77 pacientes, 24 (21.2%) pacientes murieron y 41 (53.23%) presentaron lesión renal aguda. Se observó un AUC (área bajo la curva) para LVIS 0.89 con un punto de corte de 21.3 (sensibilidad 50% y especificidad de 82%). El puntaje LVIS &gt; 21.3 con RR 2.09 (IC95% 1.15-3.7, p = 0.003) y un HR de 3.8 (IC95% 1.5-9.3, p = 0.003), LR+ 2.81 y LR- 0.61 para mortalidad. LVIS no fue significativo para predecir LRA (lesión renal aguda).  Conclusiones:  LVIS es útil para predecir mortalidad en choque séptico, con un punto de corte 21.3. Es necesario continuar estudios para validarlo en población adulta con otras formas de choque.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  Introduction:  Vasopressors have a fundamental roll in the treatment of septic shock. LVIS (levosimendan vasopressor inotropic score) as a score that integrates the main vasopressors and inotropic drugs may be useful for monitoring and prognosis. It&#8217;s been studied in pediatric population, but not validated in adult patients so far.  Material and methods:  Retrospective, longitudinal, retrolective study in adults admitted in ICU with septic shock. We looked to investigate if LVIS score is useful to predict mortality and acute kidney injury in ICU, with a follow-up of 30 days.  Results:  We included 77 patients, 24 (21.2%) patients died and 41 (53.23%) developed acute kidney injury. LVIS had an AUC of 0.89 with a cut-off of 21.3 (50% sensitivity and 82% of specificity). LVIS score above the cut-off 21.3, had RR 2.09 (CI95% 1.15-3.7, p = 0.003), HR de 3.8 (CI 1.5-9.3, p = 0.003), LR+ 2.81 and LR- 0.61 for mortality. LVIS could not predict AKI (acute kidney).  Conclusions:  LVIS score is useful to predict mortality in patients with septic shock, with a cut-off of 21.3. More research is left to be done to validate this score in other forms of shock in adult population.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo:  Introdução:  O uso de vasopressores no choque séptico é uma parte fundamental do tratamento. O uso de um escore que integra múltiplos vasopressores e drogas inotrópicas como o LVIS (Levosimendan Vasopressor Inotropic Score), pode ser útil para o acompanhamento e prognóstico desses pacientes. Foi estudado na população pediátrica e não foi validado na população adulta.  Material e métodos:  Estudo retrospectivo, longitudinal, retrolectivo em pacientes adultos admitidos na UTI com o diagnóstico de choque séptico para investigar se o escore LVIS é capaz de predizer a mortalidade e a lesão renal aguda em um acompanhamento de 30 dias.  Resultados:  Foram incluídos 77 pacientes, 24 (21.2%) pacientes morreram e 41 (53.23%) apresentaram lesão renal aguda. Uma AUC (área sob a curva) foi observada para LVIS 0.89 com um ponto de corte de 21.3 (sensibilidade 50% e especificidade 82%). O escore LVIS &gt; 21.3 com RR 2.09 (IC95% 1.15-3.7, p = 0.003) e uma HR de 3.8 (IC95% 1.5-9.3, p = 0.003), LR + 2.81 e LR -0.61 para mortalidade. O LVIS não foi significativa na predição da LRA (lesão renal aguda).  Conclusões:  O LVIS é útil para prever a mortalidade no choque séptico, com um ponto de corte de 21.3. É necessário continuar os estudos para validá-lo na população adulta com outras formas de choque.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Sepsis]]></kwd>
<kwd lng="es"><![CDATA[choque séptico]]></kwd>
<kwd lng="es"><![CDATA[mortalidad]]></kwd>
<kwd lng="es"><![CDATA[vasopresores]]></kwd>
<kwd lng="es"><![CDATA[inotrópicos]]></kwd>
<kwd lng="en"><![CDATA[Sepsis]]></kwd>
<kwd lng="en"><![CDATA[septic shock]]></kwd>
<kwd lng="en"><![CDATA[mortality]]></kwd>
<kwd lng="en"><![CDATA[vasopressors]]></kwd>
<kwd lng="en"><![CDATA[inotropic]]></kwd>
<kwd lng="pt"><![CDATA[Sepse]]></kwd>
<kwd lng="pt"><![CDATA[choque séptico]]></kwd>
<kwd lng="pt"><![CDATA[mortalidade]]></kwd>
<kwd lng="pt"><![CDATA[vasopressores inotrópicos]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Singer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Deutschman]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Seymur]]></surname>
<given-names><![CDATA[CW]]></given-names>
</name>
<name>
<surname><![CDATA[Shankar-Hari]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The third international consensus definitions for sepsis and septic shock]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2016</year>
<volume>315</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>801-10</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fleischman]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Scherag]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Adhikari]]></surname>
<given-names><![CDATA[NK]]></given-names>
</name>
<name>
<surname><![CDATA[Harlog]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Tsaganos]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assesment of global incidence and mortality of hospital- treated sepsis. Current estimate and limitations]]></article-title>
<source><![CDATA[Am J Resp Crit Care Med]]></source>
<year>2016</year>
<volume>193</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>259-72</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Daviaud]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Grimaldi]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Dechartres]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Charpentier]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Timing and causes of death in septic shock]]></article-title>
<source><![CDATA[Ann Intensive Care]]></source>
<year>2015</year>
<volume>5</volume>
<page-range>16</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Beck]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Chateau]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bryson]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
<name>
<surname><![CDATA[Pisipati]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Timing of vasopressor initiation and mortality in septic shock: a cohort study]]></article-title>
<source><![CDATA[Crit Care]]></source>
<year>2014</year>
<volume>18</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>R97</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Belleti]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Benedetto]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Biondi-Zoccai]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Leggieri]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The effect of vasoactive drugs on mortality in patients with severe sepsis and septic shock. A network meta-analysis of randomized trials]]></article-title>
<source><![CDATA[J Crit Care]]></source>
<year>2017</year>
<volume>37</volume>
<page-range>91-88</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sviri]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hashoul]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Stav]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[van Heerden]]></surname>
<given-names><![CDATA[PV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Does high-dose vasopressor therapy in medical intensive care patients indicate what we already suspect?]]></article-title>
<source><![CDATA[J Crit Care]]></source>
<year>2014</year>
<volume>29</volume>
<page-range>157-60</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Farkas]]></surname>
<given-names><![CDATA[DT]]></given-names>
</name>
<name>
<surname><![CDATA[Rahnemai-Azar]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Kunhammed]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Greenbaum]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Realistic survival outcomes after vasopressor use in the intensive care unit]]></article-title>
<source><![CDATA[Am J Hosp Palliat Care]]></source>
<year>2016</year>
<volume>33</volume>
<page-range>871-4</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Belletti]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Castro]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Silvetti]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Greco]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The effect of inotropes and vasopressors on mortality: a meta-analysis of randomized clinical trials]]></article-title>
<source><![CDATA[Br J Anaesth]]></source>
<year>2015</year>
<volume>115</volume>
<page-range>656-75</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Auchet]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Regnier]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Girend]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Levy]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Outcome of patients with septic shock and high-dose vasopressor therapy]]></article-title>
<source><![CDATA[Ann Intensive Care]]></source>
<year>2017</year>
<volume>7</volume>
<page-range>43</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Lanspa]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Kuttler]]></surname>
<given-names><![CDATA[KG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Survival after shock requiring high-dose vasopressor therapy]]></article-title>
<source><![CDATA[Chest]]></source>
<year>2013</year>
<volume>143</volume>
<page-range>664-71</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Davidson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Tong]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hancock]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Hauck]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prospective validation of the vasoactive inotropic score and correlation to short term outcomes in neonates and infants after cardiothoracic surgery]]></article-title>
<source><![CDATA[Intensive Care Med]]></source>
<year>2012</year>
<volume>38</volume>
<page-range>1184-90</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Favia]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Vitale]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Ricci]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The vasoactive -inotropic score and levosimendan: time for LVIS?]]></article-title>
<source><![CDATA[J Cardiothorac Vasc Anesth]]></source>
<year>2013</year>
<volume>27</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>e15-6</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McIntosh]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Suhong]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Deakyne]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Davidson]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Validation of the vasoactive inotropic score in pediatric sepsis]]></article-title>
<source><![CDATA[Pediatr Crit Care Med]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gordon]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Perkins]]></surname>
<given-names><![CDATA[GD]]></given-names>
</name>
<name>
<surname><![CDATA[Singer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Orme]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Levosimendan for the prevention of acute organ dysfunction in sepsis]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2016</year>
<volume>375</volume>
<page-range>1638-48</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
